AdAlta is an innovative biotech company developing a unique range of new drug treatments

AdAlta has pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases.

AdAlta is utilising the power of the i-body technology to create a pipeline of new drugs, with an initial focus on treating fibrotic diseases.


Further details on the Entitlement Offer for Eligible AdAlta Shareholders can be found here

Investors

More Info

Please join our mailing list for more information and updatesSubscribe here